HMNC Holding
Manufacturing · New York, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
211 E 43rd St, New York City, New York, ...Phone Number
(917) 764-2018Website
www.hmnc-brainhealth.comRevenue
$10 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About HMNC Holding
HMNC Brain Health is a clinical stage biopharma company focused on pioneering precision psychiatry through targeted therapies for mental health disorders. The company aims to address the high unmet medical need for superior therapeutic outcomes in patients suffering from conditions such as depression and anxiety. Utilizing state-of-the-art scientific methods and predictive diagnostics, HMNC develops personalized treatments that set new standards in psychiatric care. Their innovative approach is supported by an experienced team dedicated to transforming the therapy landscape for mental health disorders.Explore more
HMNC Holding Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is HMNC Holding your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if HMNC Holding is spiking on competitors!
Funding: Get notified immidiatlly once HMNC Holding has new funding data
Website visits: Recent activity has been detected on your website
Click to see if HMNC Holding had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
HMNC Holding, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at HMNC Holding
Product Launch: Get notified when HMNC Holding launches new products
Earning: See what the market has to say on HMNC Holding recently announced quarterly report
Check if HMNC Holding has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined HMNC Holding as Masked Content
Find 3 more new buyers
Compare Similar Companies to HMNC Holding
Compare insights from companies similar to HMNC Holding, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
HMNC Holding is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
HMNC Holding is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about HMNC Holding.
HMNC Holding financials insights
Gather financial insights about HMNC Holding, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Other Financing Round
$14M
2026
Series B
$50M
HMNC Holding Tech Stack
A closer look at the technologies used by HMNC Holding
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
Funding
Funding
Left Company
Executive Move
Executive Moves, Left Company
Event
Event
HMNC Holding News & Media
HMNC Brain Health appoints Dr. Bjørn Grønning as Chief Medical Officer
MUNICH, Germany, June 17, 2026 – HMNC Brain Health ("HMNC" or the "Company"), a clinical-stage neuroscience company, today announced the appointment of Dr. Bjørn Grønning as Chief Medical Officer (CMO), effective immediately, following the planned transition of Dr. Hans Eriksson.German biotech banks $50m Series B and partnership to advance depression therapies
HMNC secures $50m from MEDICE to advance two depression therapies, KET01 and BH-200, with European licensing deal included.HMNC Brain Health announces $50 million first closing of Series B financing and a strategic partnership with MEDICE
MUNICH, Germany, June 15, 2026 – HMNC Brain Health ("HMNC" or the "Company"), a clinical-stage neuroscience company, today announced the successful $50 million first closing of its Series B financing to support the advancement of the Company’s Ketabon (KET01) and Nelivabon (BH-200) clinical programs.Ketabon Presents New Data Showing Antidepressant Effects of Oral Ketamine (KET01) Are Independent of Dissociation
Ketabon, a JV between HMNC and Develco, shared new post hoc Phase 2 data for oral ketamine (KET01) in treatment-resistant depression (TRD)
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding HMNC Holding
Sign Up For FreeTo access detailed company insights
HMNC Brain Health is a clinical stage biopharma company focused on pioneering precision psychiatry through targeted therapies for mental health disorders. The company aims to address the high unmet medical need for superior therapeutic outcomes in patients suffering from conditions such as depression and anxiety. Utilizing state-of-the-art scientif... Read More
